Johnson & Johnson (NYSE:JNJ) Shares Bought by Mendel Money Management

Mendel Money Management raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.6% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,792 shares of the company’s stock after purchasing an additional 440 shares during the period. Mendel Money Management’s holdings in Johnson & Johnson were worth $1,983,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. DORCHESTER WEALTH MANAGEMENT Co increased its stake in Johnson & Johnson by 8.6% during the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock valued at $14,975,000 after purchasing an additional 5,327 shares in the last quarter. Cantor Fitzgerald Investment Advisor L.P increased its position in shares of Johnson & Johnson by 88.9% in the 1st quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock valued at $31,049,000 after acquiring an additional 82,429 shares during the period. AMI Investment Management Inc. raised its stake in Johnson & Johnson by 8.8% in the 1st quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock worth $3,244,000 after acquiring an additional 1,475 shares during the last quarter. Equitable Holdings Inc. grew its stake in Johnson & Johnson by 4.9% during the 1st quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock valued at $8,095,000 after purchasing an additional 2,119 shares during the last quarter. Finally, USS Investment Management Ltd increased its holdings in shares of Johnson & Johnson by 2.4% in the first quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock valued at $152,488,000 after purchasing an additional 20,528 shares during the period. Hedge funds and other institutional investors own 67.57% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Kathryn E. Wengel sold 12,465 shares of the stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the completion of the sale, the executive vice president now directly owns 65,934 shares in the company, valued at $10,549,440. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the sale, the executive vice president now owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Peter Fasolo sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the transaction, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The disclosure for this sale can be found here. Insiders have sold a total of 47,163 shares of company stock valued at $7,928,856 in the last 90 days. 0.20% of the stock is owned by insiders.

Johnson & Johnson Stock Up 1.4 %

Shares of NYSE JNJ opened at $166.25 on Friday. The firm has a market cap of $432.08 billion, a price-to-earnings ratio of 33.65, a price-to-earnings-growth ratio of 2.76 and a beta of 0.54. The company’s 50-day simple moving average is $166.68 and its 200-day simple moving average is $161.50. The company has a quick ratio of 0.88, a current ratio of 1.12 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $181.04.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.62 by $0.18. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The company had revenue of $25.53 billion for the quarter, compared to analysts’ expectations of $24.63 billion. During the same period in the previous year, the firm posted $2.59 EPS. Johnson & Johnson’s revenue was up 6.3% compared to the same quarter last year. Equities analysts predict that Johnson & Johnson will post 10.75 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Monday, August 28th will be issued a $1.19 dividend. The ex-dividend date is Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a yield of 2.86%. Johnson & Johnson’s payout ratio is currently 96.36%.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. TheStreet upgraded Johnson & Johnson from a “c+” rating to a “b+” rating in a research report on Monday. Atlantic Securities increased their price objective on shares of Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a research note on Friday, August 4th. Stifel Nicolaus boosted their target price on shares of Johnson & Johnson from $165.00 to $175.00 in a research report on Friday, July 21st. JPMorgan Chase & Co. increased their price target on Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a research report on Friday, July 21st. Finally, Morgan Stanley restated an “equal weight” rating and issued a $187.00 target price on shares of Johnson & Johnson in a research note on Friday, July 21st. Eight research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $171.80.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.